Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)

Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)

Background PD-L1 expression on tumor cells is a marker of PD-1/PD-L1 antibody treatment efficacy for advanced non-small cell lung cancer (NSCLC). PD-L1 antibody (atezolizumab) prolongs overall survival (OS) compared with platinum doublet as first-line treatment for NSCLC with high PD-L1 expression....

Full description

Saved in:
Bibliographic Details
Main Authors: Mototsugu Shimokawa, Hiroshi Tanaka, Nobuyuki Yamamoto, Koichi Azuma, Hidetoshi Hayashi, Ryo Toyozawa, Kazumi Nishino, Kazuhiko Nakagawa, Isamu Okamoto, Hideo Saka, Takashi Seto, Kaname Nosaki, Shunichi Sugawara, Haruyasu Murakami, Terufumi Kato, Seiji Niho, Masahide Oki, Hiroshige Yoshioka, Haruko Daga, Rie Tohnai
Format: Article
Language:English
Published: BMJ Publishing Group 2022-02-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/2/e004025.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/10/2/e004025.full

Similar Items